Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Trial of FIT039CT in Cervical Intraepithelial Neoplasia
jRCT2051180201Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of FIT039CT in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Adverse effect. Started Apr 2019; status: completed.
02
Drugs
FIT039CT
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on jRCT2051180201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051180201.